Skip to Main Content

SOMATIC SYMPTOM DISORDERS

Cognitive behavioral therapy has been shown to be an effective treatment for somatoform disorders by reducing physical symptoms, psychological distress, and disability.

PSYCHOSEXUAL DISORDERS

Bremelanotide is FDA-approved for the treatment of female hypoactive sexual desire disorder in premenopausal women.

SCHIZOPHRENIA SPECTRUM DISORDERS

There is early evidence that cannabidiol (CBD) is efficacious in improving psychotic symptoms in schizophrenia when added to existing antipsychotic treatment. This may represent a new class of therapy for psychotic disorders.

MOOD DISORDERS

Allopregnanolone, a neurosteroid allosteric modulator of GABA-a receptors, was approved in 2019 for the treatment of postpartum depression.

OTHER DRUG & SUBSTANCE USE DISORDERS

There is emerging evidence that there is a clinically distinct syndrome associated with vaping tetrahydrocannabinol (THC). Vaping-associated lung injury may result in devastating pulmonary effects and distinct pathophysiology.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.